Gene therapy is going to become the standard of care for inherited monogenic diseases. To improve the capabilities of current gene therapy in development, the human immune system needs to be properly modulated. Approximately 50% of the population is already immune against the common virus vehicles that are used to deliver genes to target cells. On top of that, nearly all patients will develop antibodies against the vehicles after their first dose, preventing a chance for a critical second dose.

At Serenity, we're unlocking the full potential for gene therapy through our novel immunomodulatory platform, CargoTekā„¢, by first focusing on AAV gene therapy for hemophilia.

Serenity Bioworks has large plans for the pharmaceutical industry. Serenity's CargoTekā„¢ has the potential to enhance the long-term efficacy and safety profiles for gene therapy, resulting in safe and longer-lasting treatments.